Medical device developer GT Medical Technologies has secured $53 million in funding in a Series D equity financing round.
The final close of the round constituted an additional $16 million from new investors, including FemHealth Ventures, Warren Point Capital, and an undisclosed third party, as well as participation from current institutional investors.
GT Medical Technologies announced the completion of a $37 million first close of the Series D equity financing round earlier this year. That round was led by Evidity Health Capital, along with new investor Accelmed Partners and existing investors MVM Partners, Gilde Healthcare, and Medtech Venture Partners.
The company will use the funds to expand the commercialization of its radiation therapy GammaTile in the U.S., to complete enrollment of the ROADS randomized controlled trial for newly diagnosed brain metastases, and to support an additional randomized controlled trial of its GammaTile radiation therapy system for newly diagnosed glioblastoma cases.
